Phase 3 Recruiting Academic/Other
This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk …
Sponsor: NRG Oncology
NCT ID: NCT05946213
Sites in Washington: - PeaceHealth Saint Joseph Medical Center — Bellingham, Washington
- Fred Hutchinson Cancer Center — Seattle, Washington
- FHCC at Northwest Hospital — Seattle, Washington
- University of Washington Medical Center - Montlake — Seattle, Washington
Phase 3 Recruiting Network
This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach is better o…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06592924
Sites in Washington: - Providence Regional Cancer System-Aberdeen — Aberdeen, Washington
- FHCC Overlake — Bellevue, Washington
- PeaceHealth Saint Joseph Medical Center — Bellingham, Washington
- Providence Regional Cancer System-Centralia — Centralia, Washington
- Swedish Cancer Institute-Edmonds — Edmonds, Washington
Phase 3 Recruiting Network
This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to standard of care (prostate radiation ther…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT04423211
Sites in Washington: - Providence Regional Cancer System-Aberdeen — Aberdeen, Washington
- PeaceHealth Saint Joseph Medical Center — Bellingham, Washington
- Providence Regional Cancer System-Centralia — Centralia, Washington
- Swedish Cancer Institute-Edmonds — Edmonds, Washington
- Providence Regional Cancer Partnership — Everett, Washington
Phase 3 Recruiting Network
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03678025
Sites in Washington: - FHCC Overlake — Bellevue, Washington
- Seattle Cancer Care Alliance at EvergreenHealth — Kirkland, Washington
- FHCC South Lake Union — Seattle, Washington
- FHCC at Northwest Hospital — Seattle, Washington
- University of Washington Medical Center - Montlake — Seattle, Washington
Phase 3 Recruiting Academic/Other
This randomized phase III trial examines whether lengthening the dosage interval in an adaptive manner for the prostate cancer drug lutetium 177 Lu PSMA RLT improves quality of life without decreasing lifespan when compared to the standard…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07200830
Sites in Washington: - Swedish Cancer Institute-Edmonds — Edmonds, Washington
- Swedish Medical Center-First Hill — Seattle, Washington
Phase 3 Recruiting Industry
This study will explore whether a combination of the investigational drug mevrometostat (PF-06821497) and enzalutamide will work better than taking enzalutamide alone in participants with mCSPC who are ARPI naïve and have not yet received …
Sponsor: Pfizer
NCT ID: NCT07028853
Sites in Washington: - Northwest Medical Specialties, PLLC — Bonney Lake, Washington
- Northwest Medical Specialties, PLLC — Federal Way, Washington
- Northwest Medical Specialties, PLLC — Gig Harbor, Washington
- Northwest Medical Specialties, PLLC — Puyallup, Washington
- Northwest Medical Specialties, PLLC — Tacoma, Washington
Phase 3 Recruiting Industry
The purpose of this study is to assess the efficacy and safety of opevesostat plus daily corticosteroids compared to alternative abiraterone acetate or enzalutamide in participants with Metastatic Castration-resistant Prostate Cancer (mCRP…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136650
Sites in Washington: - Spokane Urology ( Site 0035) — Spokane, Washington
- Northwest Cancer Specialists (Compass Oncology) ( Site 8008) — Vancouver, Washington
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the overall survival (length of time from the start of study to date of death from any cause) for pasritamig (JNJ-78278343) in Part 1 in combination with best supportive care (BSC) and in Part 2 wit…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07164443
Sites in Washington: - VA Puget Sound Healthcare System — Seattle, Washington
- Fred Hutchinson Cancer Research Center — Seattle, Washington
- University of Washington — Seattle, Washington
Phase 3 Recruiting Industry
This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) with respect to overall survival (OS) i…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136624
Sites in Washington: - Fred Hutchinson Cancer Center ( Site 0013) — Seattle, Washington
Phase 3 Recruiting Industry
This study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alone in participants with mCRPC who are ARSi or abiraterone naïve.
Sponsor: Pfizer
NCT ID: NCT06629779
Sites in Washington: - Northwest Medical Specialties, PLLC — Bonney Lake, Washington
- Northwest Medical Specialties, PLLC — Federal Way, Washington
- Northwest Medical Specialties, PLLC — Gig Harbor, Washington
- Northwest Medical Specialties, PLLC — Puyallup, Washington
- Harborview Medical Center — Seattle, Washington
Phase 2 Recruiting NIH
This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03866382
Sites in Washington: - Providence Regional Cancer System-Aberdeen — Aberdeen, Washington
- Overlake Medical Center — Bellevue, Washington
- PeaceHealth Saint Joseph Medical Center — Bellingham, Washington
- Highline Medical Center-Main Campus — Burien, Washington
- Providence Regional Cancer System-Centralia — Centralia, Washington
Phase 2 Recruiting Network
This phase II trial tests how well carboplatin before surgery works in treating patients with high-risk prostate cancer and an inherited BRCA1 or BRCA2 gene mutation. Carboplatin is in a class of medications known as platinum-containing co…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05806515
Sites in Washington: - Providence Regional Cancer System-Aberdeen — Aberdeen, Washington
- PeaceHealth Saint Joseph Medical Center — Bellingham, Washington
- Harrison Medical Center — Bremerton, Washington
- Providence Regional Cancer System-Centralia — Centralia, Washington
- Swedish Cancer Institute-Edmonds — Edmonds, Washington
Phase 1, Phase 2 Recruiting Industry
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…
Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in Washington: - University of Washington, Fred Hutchinson Cancer Center — Seattle, Washington
Phase 2 Recruiting Federal
This study will determine whether the presence of DNA repair deficiency in the form of alterations in the genes ATM, CDK12 or CHEK2 predicts for a high likelihood of responding to the use of intermittent high dose testosterone. This therap…
Sponsor: VA Office of Research and Development
NCT ID: NCT05011383
Sites in Washington: - VA Puget Sound Health Care System Seattle Division, Seattle, WA — Seattle, Washington
Phase 1, Phase 2 Recruiting Industry
This is a first-in-human, Phase 1/2, open-label, dose escalation, dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Peluntamig (PT217) as a m…
Sponsor: Phanes Therapeutics
NCT ID: NCT05652686
Sites in Washington: - Fred Hutch Cancer Center — Seattle, Washington
Phase 1, Phase 2 Recruiting Industry
This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible s…
Sponsor: 858 Therapeutics, Inc.
NCT ID: NCT06395519
Sites in Washington: - Fred Hutchinson Cancer Center — Seattle, Washington
Phase 2 Recruiting Industry
This Phase 2, open-label, multicenter study is conducted in patients with castration-resistant prostate cancer. Patients in this study receive MRT-2359, an investigational oral medicine, in combination with apalutamide, an oral medicine us…
Sponsor: Monte Rosa Therapeutics, Inc
NCT ID: NCT07745361
Sites in Washington: - University of Washington Medical Center — Seattle, Washington
Phase 2 Recruiting Industry
The investigators have used national VHA data to demonstrate real-world efficacy of abiraterone and enzalutamide in Veterans with mCRPC. In the real-world that is the VHA, the investigators have successfully estimated g values that accurat…
Sponsor: Sun Pharmaceutical Industries Limited
NCT ID: NCT05422911
Sites in Washington: - VA Puget Sound Health Care System — Seattle, Washington
Phase 1, Phase 2 Recruiting Industry
The purpose of this substudy is to assess the efficacy and safety of ifinatamab deruxtecan (I-DXd), given alone or with other treatments in participants with metastatic castration-resistant prostate cancer (mCRPC). The goals of this study …
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06863272
Sites in Washington: - Fred Hutchinson Cancer Center ( Site 0013) — Seattle, Washington
Phase 1, Phase 2 Recruiting Industry
This is a two-part, Phase I/II, open-label, global, multicenter study assessing the safety and efficacy of the combination of tulmimetostat (DZR123) and JSB462 (luxdegalutamide) versus standard of care in participants with progressive meta…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT07206056
Sites in Washington: - Fred Hutchinson Cancer Research Center — Seattle, Washington
Phase 2 Recruiting Academic/Other
The purpose of this study is to find out whether talazoparib in combination with enzalutamide or talazoparib alone delays cancer progression in people with metastatic castration-resistant prostate cancer (mCRPC) who have homologous recombi…
Sponsor: Prostate Cancer Clinical Trials Consortium
NCT ID: NCT06844383
Sites in Washington: - Fred Hutchinson Cancer Center — Seattle, Washington
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1 and Phase 2 study to evaluate the safety and antitumor activity of INV-9956 in adult patients with advanced metastatic Castration Resistant Prostate Cancer.
Sponsor: Shenzhen Ionova Life Sciences Co., Ltd.
NCT ID: NCT06609005
Sites in Washington: - Summit Cancer Centers — Spokane, Washington
Phase 2 Recruiting Academic/Other
The objective of this study is to see if providing an appropriate therapy based on the genomic testing of prostate tumour tissue will result in an improved clinical response. Each participant will be treated with 8 weeks of a luteinizing h…
Sponsor: University of British Columbia
NCT ID: NCT04812366
Sites in Washington: - Fred Hutchinson Cancer Center — Seattle, Washington
Phase 2 Recruiting Academic/Other
The goal of this clinical trial is to measure the toxicity and effectiveness of the following treatments for cFIR/cgUIR prostate cancer patients. Stereotactic body radiotherapy (SBRT) alone or Stereotactic body radiotherapy (SBRT) combined…
Sponsor: Yale University
NCT ID: NCT06111781
Sites in Washington: - University of Washington — Seattle, Washington
Phase 1, Phase 2 Recruiting Academic/Other
This phase I/II trial tests the safety and effectiveness of cell therapy (STEAP1 CART) with enzalutamide in treating patients with prostate cancer that continues to grow despite surgical or medical treatments to block androgen production (…
Sponsor: Fred Hutchinson Cancer Center
NCT ID: NCT06236139
Sites in Washington: - Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington